Findings

What do systematic reviews say?

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Nebulized budesonide vs viscous budesonide

Withdrawals due to adverse events · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Viaskin milk patch vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

FEV1 % predicted · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

FVC · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Growth and nutritional status · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention

Incidence of PDR/CSME/VH by 5 years · type 1 or type 2 diabetics

1 finding from 1 review

Blood pressure control for diabetic retinopathy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · type 1 or type 2 diabetics

It is very uncertain whether blood pressure intervention/intensive blood pressure intervention changes visual acuity (loss of 3 lines or more) by 5 years compared with placebo/standard blood pressure intervention (very low certainty).

1 finding from 1 review

Blood pressure control for diabetic retinopathy 2023 · Cochrane Headline outcomes only
RR 1.15 [0.63, 2.08]
2 studies · 2326 participants
Very low

Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention

Adverse events—all‐cause mortality · type 1 or type 2 diabetics

1 finding from 1 review

Blood pressure control for diabetic retinopathy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Blood pressure intervention/intensive blood pressure intervention vs placebo/standard blood pressure intervention

Adverse events: hypotension · type 1 or type 2 diabetics

Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).

1 finding from 1 review

Blood pressure control for diabetic retinopathy 2023 · Cochrane Headline outcomes only
RR 2.04 [1.63, 2.55]
2 studies · 3323 participants
Low

Intervention not reported

Gestational diabetes mellitus · pregnant women (women with pre‐existing type 1 or type 2 diabetes are NOT included)

It is very uncertain whether the intervention changes gestational diabetes mellitus (very low certainty).

1 finding from 1 review

Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes 2023 · Cochrane Headline outcomes only
RR 0.53 [0.31, 0.9]
6 studies · 1140 participants
Very low